Ligand Pharmaceuticals Debt

LGND Stock  USD 120.62  1.43  1.20%   
Ligand Pharmaceuticals holds a debt-to-equity ratio of 0.18. At present, Ligand Pharmaceuticals' Short and Long Term Debt is projected to decrease significantly based on the last few years of reporting. The current year's Cash Flow To Debt Ratio is expected to grow to 1.70, whereas Net Debt is projected to grow to (15.9 M). . Ligand Pharmaceuticals' financial risk is the risk to Ligand Pharmaceuticals stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Ligand Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Ligand Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Ligand Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Ligand Pharmaceuticals' stakeholders.
For most companies, including Ligand Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Ligand Pharmaceuticals Incorporated, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Ligand Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
2.7095
Book Value
44.839
Operating Margin
0.2114
Profit Margin
0.2968
Return On Assets
0.013
As of November 26, 2024, Total Current Liabilities is expected to decline to about 15.9 M. In addition to that, Liabilities And Stockholders Equity is expected to decline to about 451.3 M
  
Check out the analysis of Ligand Pharmaceuticals Fundamentals Over Time.

Ligand Pharmaceuticals Bond Ratings

Ligand Pharmaceuticals Incorporated financial ratings play a critical role in determining how much Ligand Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Ligand Pharmaceuticals' borrowing costs.
Piotroski F Score
6
HealthyView
Beneish M Score
(3.83)
Unlikely ManipulatorView

Ligand Pharmaceuticals Debt to Cash Allocation

Many companies such as Ligand Pharmaceuticals, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Ligand Pharmaceuticals Incorporated currently holds 6.17 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Ligand Pharmaceuticals has a current ratio of 1.42, which is within standard range for the sector. Note, when we think about Ligand Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Ligand Pharmaceuticals Total Assets Over Time

Ligand Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Ligand Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Ligand Pharmaceuticals Debt Ratio

    
  11.0   
It looks as if most of the Ligand Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Ligand Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Ligand Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Ligand Pharmaceuticals Corporate Bonds Issued

Most Ligand bonds can be classified according to their maturity, which is the date when Ligand Pharmaceuticals Incorporated has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Ligand Short Long Term Debt Total

Short Long Term Debt Total

5.86 Million

At present, Ligand Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.

Understaning Ligand Pharmaceuticals Use of Financial Leverage

Ligand Pharmaceuticals' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Ligand Pharmaceuticals' total debt position, including all outstanding debt obligations, and compares it with Ligand Pharmaceuticals' equity. Financial leverage can amplify the potential profits to Ligand Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Ligand Pharmaceuticals is unable to cover its debt costs.
Last ReportedProjected for Next Year
Short and Long Term Debt Total6.2 M5.9 M
Net Debt-16.8 M-15.9 M
Short Term Debt410 K389.5 K
Long Term Debt368.8 M387.3 M
Long Term Debt Total368.8 M259.4 M
Short and Long Term Debt69 M125.1 M
Net Debt To EBITDA(0.17)(0.16)
Debt To Equity 0.12  0.11 
Interest Debt Per Share 0.04  0.04 
Debt To Assets 0.12  0.11 
Long Term Debt To Capitalization 0.32  0.31 
Total Debt To Capitalization 0.13  0.12 
Debt Equity Ratio 0.12  0.11 
Debt Ratio 0.12  0.11 
Cash Flow To Debt Ratio 1.62  1.70 
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.032
Earnings Share
2.48
Revenue Per Share
8.509
Quarterly Revenue Growth
0.576
Return On Assets
0.013
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.